---
layout: post
title: "Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment; Guidance for Industry; Availability"
date: 2026-02-05 18:58:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-07397
original_published: 2022-04-07 00:00:00 +0000
significance: 8.00
---

# Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 07, 2022 00:00 UTC
**Document Number:** 2022-07397

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drugs and biologics for the treatment of chronic hepatitis B virus (HBV) infection from the initial investigational new drug application (IND) through the new drug application (NDA)/biologics license application (BLA) and postmarketing phases. This guidance finalizes the draft guidance of the same title issued on November 2, 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/07/2022-07397/chronic-hepatitis-b-virus-infection-developing-drugs-for-treatment-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-07397

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
